Literature DB >> 9713165

Hematopoietic growth factors and marrow stroma in aplastic anemia.

S Koijima1.   

Abstract

An abnormal bone marrow microenvironment and hematopoietic growth factors are considered as one of the possible mechanisms of aplastic anemia. Circulating levels of erythropoietin, granulocyte colony-stimulating factor (G-GSF), granulocyte-macrophage colony-stimulating factor (GM-GSF) and thrombopoietin are significantly higher in patients with aplastic anemia than in normal controls. Of the two hematopoietic growth factors, acting at the early stages of hematopoiesis, circulating levels of flt-3 ligand are highly elevated in patients with aplastic anemia, whereas those of stem cell factor (SCF) are essentially normal. Decreased production has been described only for interleukin (IL) 1. This may reflect defective monocyte-macrophage maturation in patients with aplastic anemia. Marrow stromal cells are thought to exert a regulatory role in hematopoiesis, at least in part, by the production of certain hematopoietic growth factors. The abilities of stromal cells to produce hematopoietic growth factors, including G-GSF, GM-CSF, IL-6 and SCF, are either normal or elevated in the majority of patients. Thus, the deficiencies of hematopoietic growth factors are unlikely to be the cause of aplastic anemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713165     DOI: 10.1016/s0925-5710(98)00028-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  2 in total

1.  Dendritic cell, monocyte, B and NK lymphoid deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic syndrome.

Authors:  Venetia Bigley; Matthew Collin
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

2.  Linking hematopoiesis to endochondral skeletogenesis through analysis of mice transgenic for collagen X.

Authors:  Olena Jacenko; Douglas W Roberts; Michelle R Campbell; Patricia M McManus; Catherine J Gress; Zhuliang Tao
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.